Crohn Disease Clinical Trials

34 studies are recruiting for crohn disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

  1. A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

    The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

    Stage
    Not phased
    Ages
    18 and older
    Site
    BAMC, Houston, Texas
    Run by
    Janssen Scientific Affairs, LLC
  2. Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

    Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in …

    Stage
    Phase 3
    Ages
    Any age
    Site
    Connecticut Clinical Research Institute ( Site 0297), Bristol, Connecticut
    Locations
    37 in total
    Run by
    Merck Sharp & Dohme LLC
  3. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

    The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    AZ Gastro Care, Chandler, Arizona
    Locations
    395 in total
    Run by
    Janssen Research & Development, LLC
  4. A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

    The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Digestive Health Specialists of the Southeast, Dothan, Alabama
    Locations
    164 in total
    Run by
    Janssen Research & Development, LLC
  5. A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

    The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intesti…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mayo Clinic, Scottsdale, Arizona
    Locations
    287 in total
    Run by
    Janssen Research & Development, LLC
  6. A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

    The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications. This is a fully remote (virtual) study. Participan…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Run by
    Janssen Research & Development, LLC
  7. Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

    This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    University of Miami, Miami, Florida
    Locations
    8 in total
    Run by
    Alimentiv Inc.
  8. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

    Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adu…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Biopharma Informatic, LLC, Los Angeles, California
    Locations
    70 in total
    Run by
    Eli Lilly and Company
  9. A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

    The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protoc…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Om Research LLC, Oxnard, California
    Locations
    70 in total
    Run by
    Eli Lilly and Company
  10. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California Davis Comprehensive Cancer Center, Sacramento, California
    Locations
    52 in total
    Run by
    National Cancer Institute (NCI)
  11. Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

    The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease.

    Stage
    Not phased
    Ages
    18 to 75
    Site
    Massachusetts General Hospital, Boston, Massachusetts
    Run by
    Massachusetts General Hospital
  12. Standardized Microbiota Transplant Therapy in Crohn's Disease

    Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation …

    Stage
    Phase 2
    Ages
    18 to 89
    Site
    University of Minnesota, Minneapolis, Minnesota
    Locations
    3 in total
    Run by
    University of Minnesota
  13. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

    The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mayo Clinic Arizona, Scottsdale, Arizona
    Locations
    24 in total
    Run by
    Mayo Clinic
  14. Low Dose IL-2 for the Treatment of Crohn's Disease

    The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

    Stage
    Phase 1
    Ages
    12 to 80
    Site
    Boston Children's Hospital, Boston, Massachusetts
    Locations
    3 in total
    Run by
    Boston Children's Hospital
  15. Autologous Stem Cell Transplant for Crohn's Disease

    Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflamm…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai, New York, New York
    Run by
    Aaron Etra
  16. Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

    This research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for inflammatory bowel disease. This research will increase the understanding of the role of a self-management program in improving health and health-related quality of life for patient…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Micigan, Ann Arbor, Michigan
    Run by
    University of Michigan
  17. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

    This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

    Stage
    Not phased
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center
  18. Precise Infliximab Exposure and Pharmacodynamic Control

    Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The ma…

    Stage
    Phase 2
    Ages
    6 to 22
    Site
    Children's Hospital of Los Angeles, Los Angeles, California
    Locations
    11 in total
    Run by
    Children's Hospital Medical Center, Cincinnati
  19. Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

    This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut in…

    Stage
    Not phased
    Ages
    6 to 21
    Site
    Seattle Children's Hospital, Seattle, Washington
    Run by
    Seattle Children's Hospital
  20. COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

    The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (T…

    Stage
    Not phased
    Ages
    1 to 18
    Site
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Locations
    4 in total
    Run by
    University of North Carolina, Chapel Hill
  21. Therapeutic Endpoint in Pediatric IBD Conditions

    The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory respo…

    Stage
    Not phased
    Ages
    6 to 21
    Site
    Children's National Health System, Washington D.C., District of Columbia
    Run by
    Children's National Research Institute
  22. Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

    In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the collagen-binding radiotracer will be performed. The study aims to establish the performance figures of PET/MR using [68Ga]CBP8-PET f…

    Stage
    Not phased
    Ages
    18 to 99
    Site
    Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
    Run by
    Massachusetts General Hospital
  23. Impact of Prebiotics in Ulcerative Colitis

    The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve…

    Stage
    Not phased
    Ages
    18 to 85
    Site
    UCLA, Los Angeles, California
    Run by
    University of California, Los Angeles
  24. Effect of Statins on Crohn's Disease

    The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is: * Can statins reduce the formation of strictures in participants with stricturing Crohn's disease? Researchers will compare statins to a placebo …

    Stage
    EARLY_Phase 1
    Ages
    18 to 80
    Site
    Stanford University, Stanford, California
    Run by
    Stanford University
  25. Stem Cell Transplantation in Crohn's Disease

    Unfortunately, some patients with Crohn's disease (CD) fail to respond to the best clinical treatments and some only experience temporary benefit. For severe Crohn's disease, there is an experimental treatment called "high dose immunoablation" followed by autologous hematopoietic stem cell transpla…

    Stage
    Phase 1
    Ages
    13 to 28
    Site
    Cedars-Sinai Medical Center, Los Angeles, California
    Run by
    Cedars-Sinai Medical Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.